The mechanism of carbamazepine aggravation of absence seizures

Lige Liu, Thomas Zheng, Margaret J. Morris, Charlott Wallengren, Alison L. Clarke, Christopher A. Reid, Steven Petrou, Terence J. O'Brien

Research output: Contribution to journalArticleResearchpeer-review

62 Citations (Scopus)

Abstract

Carbamazepine (CBZ) aggravates many generalized seizures types, particularly absence seizures, but the mechanisms underlying this are poorly understood. GABA signaling within the reticular nucleus (Rt) and the ventrobasal complex (VB) of the thalamus is critical to the neurophysiology of absence seizures. The hypothesis that CBZ aggravates absence seizures by acting at the VB thalamus via a GABAA receptor-mediated mechanism was investigated in a genetic rat model, generalized absence epilepsy rats from Strasbourg (GAERS). Seizure activity was quantified by a 90-min electroencephalogram recording postdrug injection. Intracerebroventricular injections of CBZ (15 μg in 4 μl) resulted in seizure aggravation versus vehicle treatment, with a mean increase in seizure time of 40%. This indicates that CBZ acts directly, rather than via a metabolite, on the brain to aggravate seizures. Seizure aggravation also occurred following bilateral microinjection of CBZ (0.75 μg in 0.2 μl) into the VB (53%) but not following injection into the Rt (-9%). However, seizure aggravation was blocked when the GABAA receptor antagonist, bicuculline (BIC, 0.04 μg in 0.2 μl), was coinjected with CBZ into the VB. Injection of BIC alone (versus vehicle) into the VB also blocked seizure aggravation following systemic administration of CBZ (15 mg/kg i.p.). In vitro studies in Xenopus oocytes expressing recombinant GABAA receptors demonstrated that CBZ produced a dose-dependent potentiation of the GABA current at a physiological relevant concentration range (1-100 μM). These data demonstrate that CBZ acts at the VB thalamus to aggravate absence seizures in GAERS and that activation of GABAA receptors is critical to this effect.

Original languageEnglish
Pages (from-to)790-798
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume319
Issue number2
DOIs
Publication statusPublished - 2006
Externally publishedYes

Cite this